Kajian Literatur: Tinjauan Remdesivir sebagai Pilihan Terapi pada COVID–19

Wien Maryati Awdisma; Ulfa Syafli Nosa; Didik Hasmono; Nurmainah Nurmainah

doi:10.20527/jps.v8i2.11650

Kajian Literatur: Tinjauan Remdesivir sebagai Pilihan Terapi pada COVID–19

Wien Maryati Awdisma, Ulfa Syafli Nosa, Didik Hasmono, Nurmainah Nurmainah

Abstract

Infeksi virus corona baru, pertama kali terdeteksi pada akhir Desember 2019, dengan jumlah kasus terkonfirmasi lebih dari 33 juta kasus dan lebih dari 900.000 kematian dilaporkan. Terdefinisi sebagai pandemi, dan belum ada “obat khusus” yang dianggap dapat mengatasinya. Salah satu pendekatan terapeutik yang sedang dievaluasi dalam berbagai uji klinis adalah saat ini adalah remdesivir,telah disetujui oleh Badan Pengawas Obat dan Makanan (BPOM sebagai obat Emergency Use Authorization (EUA) sebagai opsi penggunaan darurat Tujuan penulisan ini untuk memberikan gambaran tentang penemuan remdesivir, mekanisme aksi, dan penelitian terkini yang mengeksplorasi efektivitas klinisnya. Metode penelitian dilakukan dengan pencarian sumber data PubMed, Google Scholar, Science Direct dan Cochrane hingga November 2020 dengan kata kombinasi kata kunci Convalescent Plasma”; “SARS-CoV-2”, Virus Corona dan dibatasi pada jurnal berbahasa Inggris. yang mengulas penemuan remdesivir, mekanisme kerja, farmakokinetik, farmakodinamik, dan efikasi uji klinis remdesivir dalam pengobatan pasien COVID-19. Kesimpulan dari penelitian ini bahwa remdesivir memiliki efek klinis yang baik setelah 10 hari pengobatan pada pasien COVID-19.

Kata Kunci: COVID-19, EUA, Remdesivir, SARS-CoV-2

The new coronavirus infection identified at the end of December 2019 and is receiving a lot of attention around the world. Globally, the number of confirmed cases has increased to more than 33 million cases and more than 900,000 deaths have been reported. This condition is defined as a pandemic situation, and so far no "special drug" is believed to be able to overcome it. One therapeutic approach currently being evaluated in various clinical studies is remdesivir. This drug is approved by the Food and Drug Administration (BPOM) as Emergency Medicine (EUA). This emergency option for remdesivir is considered a promising option for treating patients with COVID19. The purpose of this paper is to provide an overview of recent studies investigating the discovery of remdesivir, its mechanism of action, and its clinical efficacy. The survey method was conducted by searching the data sources of PubMed, Google Scholar, Science Direct, and Cochrane until November 2020. Researchers limit literary studies to English journals. The results of 1000 articles searched that met the selection criteria were 10 articles examining the results of remdesivir, its mechanism of action, pharmacokinetics, pharmacodynamics, and the efficacy of clinical remdesivir in the treatment of patients with COVID 19. The conclusion of this study is that remdesivir has a good clinical effect 10 days after treatment of patients with COVID19.

Keywords

COVID-19, EUA, Remdesivir, SARS-CoV-2

Full Text:

PDF

References

Agostini ML, Andres EL, Sims AC, et al.(2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 9(2):1-15. doi:10.1128/mBio.00221-18

De Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. (2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 117(12):6771-6776.doi:10.1073/pnas.1922083117

European Medicines Agency. (2020, April) Human Medicines Division. Summary on compassionate use. Remdesivir Gilead. Product No. EMEA/H/K/5622/CU.2020;31(April):42-44. https://www.ema.europa.eu/en/documents/other/summarycompassionate-use-remdesivirgilead_en.pdf

Food and Drug Administration. (2020) Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Remdesivir. Badan POM, the Indonesia Food and Drug Administration. http://pionas.pom.go.id

Food and Drug Administration. (2020,June,9) Taiwan Food and Drug Administration approves Remdesivir to treat patients with severe COVID-19 disease [media release] http://www.fda.gov.tw

Gandhi, Z., Mansuri, Z., & Bansod, S. (2020). Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective. SN comprehensive clinical medicine, 1–2. Advance online publication. https://doi.org/10.1007/s42399-020-00462-2

Gilead Sciences. (2020) Fact sheet for health care providers emergency use authorization (EUA) of remdesivir. http://www.fda.gov

Gilead Sciences. (2020) Gilead’s InvestigationalAntiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19 https://www.gilead.com

Gilead Sciences.(2020) Veklury for intravenous injection 100 mg: Japanese prescribing information https://www.pmda.go.jp

Gilead Sciences. (2020, October, 2) European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19 https://www.gilead.com

Gilead Sciences. (2020) Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants With Severe Coronavirus Disease (COVID-19)https://clinicaltrials.gov

Gilead Sciences Canada Inc.(2020) Health Canada Grants Marketing Authorization with Conditions (NOC/c) for Gilead’s Veklury® (Remdesivir) for the Treatment of Coronavirus Disease 2019 (COVID-19)https://www.newswire.ca.

Gilead Science Canada Inc. (2020). Product Monograph: Remdesivir for Injection; Remdesivir Solution for Injection.; 2020 www.gilead.ca

Gilead Sciences Ireland. (2020).Veklury (remdesivir): EU summary of productcharacteristics. https://www.ema.europa.eu

Gilead Sciences. (2020) Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment.https://www.clinicaltrials.gov

Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Danielle PP, Gotte M. (2020) Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. JBiol Chem, 295(20):6785-6797.doi:10.1074/jbc.RA120.013679

Grein J, Ohmagari N, Shin D, et al.(2020) Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med, 382(24):2327-2336. http://doi:10.1056/NEJMoa2007016

Li J, Fan JG. (2020,August,8) Characteristics and mech-anism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol.:13-17. doi:10.14218/JCTH.2020.00019

Liang C, Tian L, Liu Y, Hui N, Qiao G, Li H, Shi Z, Tang Y, Zhang D, Xie X, Zhao X.(2020). A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. Eur J Med Chem.;201:112527.doi:10.1016/j.ejmech.2020.112527

Morse JS, Lalonde T, Xu S, Liu WR.(2020) Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem,21(5):730-738. doi:10.1002/cbic.202000047

Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303. http://doi:10.1056/NEJMoa1910993

National Institute of Allergy and Infectious Disease (NIAID).(2020) Adaptive COVID-19 Treatment Trial(ACTT) https://clinicaltrials.gov

Nicola M,Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Losifisid C, Agha M, Agha R. (2020). The socio- economic implications of the coronavirus pandemic (COVID-19): A review Int J Surg.78(March:185-193http://doi:10.1016/j.ijsu.2020.04.018

Nili A, Farbod A, Neishabouri A, Mozafarihashjin M, Tavakolpour S, Mahmoudi H. (2020). Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.. http://doi:10.1002/rmv.2133

Pardo J, Shukla AM, Chamarthi G, Gupte A. (2020) The journey of remdesivir: From Ebola to COVID-19. Drugs Context. 9 doi:10.7573/DIC.2020-4-14

Pharmaceutical and Medical Devices Agency.(2020) Special Approval for Emergency on Remdesivir for COVID-19.https://www.pmda.go.jp

Pruijssers AJ, George AS, Schäfer A, Baric RS, Denison MR, Sheahan TP. (2020). Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020;32(3).doi:10.1016/j.celrep.107940

Q Fan; B Zhang; J Ma; S Zhang. (2020) Safety profile of the antiviral drug remdesivir: An update. Biomed Pharmacother. 2020;130:110532. doi:10.1016/j.biopha.110532

Russell B, Moss C, Rigg A, Hopkins C, Papa S, Van Hemelrijck M.(2020).Anosmia and ageusia are emerging as symptoms in patients with COVID-19:What does the current evidence say? Ecancermedicalscience.14:9-10. http://doi:10.3332/ecancer.2020.ed9 8

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB.(2020) Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J Am Med Assoc.323(18):1824-1836. http://doi:10.1001/jama.2020.6019

Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. (2020) Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More. Arch Med Res, 51(6):585-586. doi:10.1016/j.arcmed.2020.05.001

Sheahan TP, Sims AC, Graham RL, et al. (2020). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med, 9(396):1-11 doi:10.1126/scitranslmed.aal3653

Siegel D, Hui HC, Doerffler E, et al.(2017) Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. (5):1648-1661. doi:10.1021/acs.jmedchem.6b01594

Tchesnokov EP, Feng JY, Porter DP, Götte M. (2019). Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 11(4):1-16. doi:10.3390/v11040326

The Korean Bizwire.(2020) S. Korea Allows Marketing Authorization of Remdesivir [media release]. https://www.firstwordpharma.com

Therapeutic Goods Administration. Australia’s first COVID treatment approved [media release]. https://www.tga.gov.au

Wang Y, Zhang D, Du G, et al.(2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (10236):1569-1578. http://doi:10.1016/S01406736(20)31022-9

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G.(2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30:269-271. doi:10.1038/s41422-020-0282-0

Warren TK, Jordan R, Lo MK, et al.(2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature.;531(7594):381-385. http://doi:10.1038/nature17180

Williamson BN, Friederike F, Schwarz B, et al.(2020, March, 9) Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Hum Vaccines Immunother. 105933. doi: 10.1038/s41586-020-2423-5

World Health Organization. WHO Coronavirus Disease (COVID-19). Accessed September 28, 2020. https://COVID19.who.int/

Yang, K. (2020). What do we know about remdesivir drug interactions? Clinical and Translational Science. doi:10.1111/cts.12815

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y.(2020) Prevalence of comorbidities and its effects in coronavirus disease patients: A systematic review and meta-analysis. Int J Infect Dis.;94:91-95. http://doi:10.1016/j.ijid.2020.03.017

DOI: http://dx.doi.org/10.20527/jps.v8i2.11650